Anquan Shang | Medicine | Best Researcher Award

Prof. Anquan Shang | Medicine | Best Researcher Award

The Second People’s Hospital of Lianyungang | China

Prof. Anquan Shang is a distinguished Associate Chief Laboratory Technician and Clinical Laboratory Physician with an H-index of 26. At the age of 39, he has made significant contributions to the field of clinical laboratory diagnostics. As a master’s supervisor, he plays a crucial role in mentoring future medical professionals. He is currently affiliated with Shanghai Jiao Tong University and has extensive experience in tumor marker research and clinical diagnostics.

Profile👤

ORCID

Google Scholar

Scopus

Strengths for the Awards✨

  • Strong Research Productivity 

    • H-index of 26, indicating high citation impact.
    • Over 70 SCI and core journal publications as first or corresponding author.
    • Multiple high-impact factor papers in oncology, microbiology, and immunology.
  • Impressive Funding & Grants 

    • Secured multiple national and provincial-level research grants.
    • Led and participated in 13+ major projects in oncology, infection, and precision diagnostics.
  • Leadership & Recognition 

    • Head of key clinical departments and training programs in prestigious hospitals.
    • Recognized in Shanghai and Jiangsu talent programs, highlighting academic excellence.
  • Significant Innovations & Impact 

    • Contributions to liquid biopsy, tumor biomarkers, and infection diagnostics.
    • 5+ patents, demonstrating translational research impact.
  • Professional Network & Influence 

    • Active in national and international research communities.
    • Reviewer and editor for multiple scientific journals.

🎓 Education

His academic journey began with a specialization in medical laboratory technology at Xiangfan Vocational and Technical College (2005-2008). He then pursued a bachelor’s degree in medical laboratory science at Jiangsu University (2011-2014), followed by a master’s degree in clinical laboratory diagnostics at Ningxia Medical University (2014-2017). He furthered his expertise with a Ph.D. in clinical laboratory diagnostics from Tongji University (2017-2020), establishing a strong foundation for his research career.

🏥 Experience

Currently, he is a postdoctoral researcher in clinical laboratory diagnostics at Ruijin Hospital, affiliated with Shanghai Jiao Tong University (2025-present), focusing on tumor biomarker research. Since 2023, he has led the Clinical Laboratory Medicine Department at Lianyungang Second People’s Hospital, a key clinical specialty in Jiangsu Province. Previously, he completed another postdoctoral fellowship at Tongji University (2020-2022), researching tumor microenvironment and biomarkers. His clinical experience spans roles as a laboratory technician at various hospitals between 2008 and 2014, steadily advancing to leadership positions.

🔬 Research Interests On Medicine

His research focuses on:

1️⃣ Tumor immunology 🧬

2️⃣ Infection microecology and immune microenvironment remodeling 🦠

3️⃣ Precision molecular diagnostics for chronic diseases 🏥

4️⃣ Liquid biopsy techniques for early disease detection 💉

🏆 Awards

He has received numerous prestigious awards, including the Yancheng City Natural Science Achievement Award (3 times), the Yancheng Medical New Technology Introduction Award (5 times), and the Huaihai Science and Technology Progress Award (2nd Prize, twice). From 2019-2022, he was consecutively recognized as an Outstanding Young Scientific Researcher by the Shanghai Medical Association Laboratory Medicine Branch.

📚 Publications

  • Title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis
    Authors: A Shang, C Gu, W Wang, X Wang, J Sun, B Zeng, C Chen, W Chang, …
    Publication Year: 2020
    Citations: 372

  • Title: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Authors: A Shang, W Wang, C Gu, C Chen, B Zeng, Y Yang, P Ji, J Sun, J Wu, …
    Publication Year: 2019
    Citations: 147

  • Title: Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression
    Authors: A Shang, C Gu, C Zhou, Y Yang, C Chen, B Zeng, J Wu, W Lu, W Wang, …
    Publication Year: 2020
    Citations: 100

  • Title: Tumor microenvironment: lactic acid promotes tumor development
    Authors: Y Gao, H Zhou, G Liu, J Wu, Y Yuan, A Shang
    Publication Year: 2022
    Citations: 80

  • Title: Exosomal miR-183-5p promotes angiogenesis in colorectal cancer by regulation of FOXO1
    Authors: A Shang, X Wang, C Gu, W Liu, J Sun, B Zeng, C Chen, P Ji, J Wu, …
    Publication Year: 2020
    Citations: 77

  • Title: Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
    Authors: AQ Shang, J Wu, F Bi, YJ Zhang, LR Xu, LL Li, FF Chen, WW Wang, …
    Publication Year: 2017
    Citations: 77

  • Title: Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p
    Authors: AQ Shang, WW Wang, YB Yang, CZ Gu, P Ji, C Chen, BJ Zeng, JL Wu, …
    Publication Year: 2019
    Citations: 70

  • Title: IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
    Authors: J Cui, J Tian, W Wang, T He, X Li, C Gu, L Wang, J Wu, A Shang
    Publication Year: 2021
    Citations: 62

  • Title: miR‐381‐3p restrains cervical cancer progression by downregulating FGF7
    Authors: A Shang, C Zhou, G Bian, W Chen, W Lu, W Wang, D Li
    Publication Year: 2019
    Citations: 62

  • Title: Vaginal microecological characteristics of women in different physiological and pathological period
    Authors: L Shen, W Zhang, Y Yuan, W Zhu, A Shang
    Publication Year: 2022
    Citations: 59

🔚 Conclusion

With a strong academic background, leadership in clinical laboratory medicine, and groundbreaking research in tumor immunology and molecular diagnostics, he continues to make significant contributions to medical science. His extensive experience, prestigious awards, and influential publications highlight his dedication to advancing clinical diagnostics and improving patient outcomes.

Qianghua Lv | Medicine | Best Researcher Award

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Qinghong He | Health Economics | Best Researcher Award

Dr. Qinghong He | Health Economics | Best Researcher Award

Assistant Researcher | Chinese Academy of Social Sciences | China

Qinghong He is an Assistant Researcher at the Institute of Economics, Chinese Academy of Social Sciences. She specializes in health economics, hospital management, and health policy evaluation. Her work has significantly contributed to understanding healthcare efficiency and policy impacts in China. She has been an integral part of the National Natural Science Foundation of China (NSFC) project, “Hospital Management Intervention in China Based on the World Management Survey (WMS),” which received an excellence award. Her research is widely recognized, with publications in esteemed journals such as Social Science & Medicine and the International Journal of Health Policy and Management.

Profile👤

ORCID

Strengths for the Awards🎗️

Strong Research Background – Qinghong He has a PhD in Applied Economics and specializes in health economics, hospital management, and health policy evaluation, areas that have significant social impact.
Quality Publications – Her research has been published in high-impact journals such as Social Science & Medicine and the International Journal of Health Policy and Management. These are well-respected in the field of health policy and economics.
Impactful Research – Her study on the Separating Drug Sales from Treatment (SDST) policy shows a direct, measurable impact on reducing medical disputes. This has both academic and policy relevance, making her work valuable for decision-makers in healthcare.
Recognition & Research Grants – She has been a key team member in a National Natural Science Foundation of China (NSFC) project, which received an Excellence Award—a significant mark of credibility and recognition.
Diverse Research Involvement – With four completed or ongoing research projects, she demonstrates consistent engagement in advancing knowledge.

Qinghong He is a strong contender for the Best Researcher Award, especially considering her contributions to health economics and policy evaluation. Her research is timely, impactful, and relevant to global healthcare challenges, particularly in hospital management and medical dispute resolution. However, to further strengthen her candidacy, she could focus on increasing citations, industry collaborations, and editorial/leadership roles.

Education 🎓

Qinghong He earned her Ph.D. in Applied Economics from Southwestern University of Finance and Economics in June 2020. Her academic journey has been centered on healthcare policy analysis and hospital management efficiency, equipping her with a deep understanding of economic applications in public health.

Experience 💼

As an Assistant Researcher at the Institute of Economics, Chinese Academy of Social Sciences, Qinghong He actively engages in research projects focused on improving hospital management and evaluating healthcare policies. She has collaborated with esteemed scholars in the field and played a crucial role in shaping evidence-based healthcare reforms.

Research Interests On Health Economics 📝

Her research interests include:

  • Health Economics
  • Hospital Management
  • Health Policy Evaluation
  • Patient-Physician Relationships
  • Public Healthcare Systems Efficiency

Awards 🏆

  • Excellence Award for the NSFC project “Hospital Management Intervention in China Based on the World Management Survey (WMS)”

Publications 📚

Here are the publication details for Qinghong He:

  • Effects of Separating Drug Sales from Treatment on Medical Disputes

    • Authors: HE QINGHONG, Gordon G. Liu, Xiangbo Liu, Daisheng Tang
    • Publication Year: 2025
    • Journal: Social Science & Medicine
    • DOI: 10.1016/j.socscimed.2025.117781
    • Citations: (Check citation count online for accuracy)
  • How Does Management Matter for Hospital Performance? Evidence From the Global Hospital Management Survey in China

    • Authors: Qinghong He, Gordon G. Liu, Jinyang Chen, Luoqi Yuan, Xuezhi Hong, Zhihua Zhang
    • Publication Year: 2024
    • Journal: International Journal of Health Policy and Management
    • DOI: 10.34172/ijhpm.8478
    • Citations: (Check citation count online for accuracy)

Conclusion 🎯

Qinghong He’s research significantly contributes to improving hospital efficiency and healthcare policies. Her studies on medical disputes and hospital management provide empirical insights that influence policy formulation and implementation. By focusing on enhancing patient-physician relationships and healthcare management, her work has the potential to shape global healthcare policies. Her dedication to rigorous research and policy analysis marks her as a notable figure in health economics and hospital management.

Qun Zhao | Medicine | Outstanding Scientist Award

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
    • Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
    • Publication Year: 2024
    • DOI: 10.1016/j.isurg.2024.01.004
  • Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
    • Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13298
  • Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
    • Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13304
  • Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
    • Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
    • Publication Year: 2022
    • DOI: 10.1007/s00464-021-08630-8
  • Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
    • Publication Year: 2021
    • DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.

Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Dr. Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Epidemiologist | Pfizer UK Ltd | United Kingdom

Dr. Andrew Vyse is a seasoned epidemiologist with extensive experience in both the pharmaceutical industry and public health research. He specializes in vaccine-preventable and potentially vaccine-preventable infections, contributing significantly to the field with over 80 peer-reviewed publications.

Profile

Scopus

Strengths for the Awards

  • Prolific Research Contributions:
    • Dr. Vyse has authored over 80 peer-reviewed publications, which demonstrates a consistent and significant contribution to epidemiological research, particularly in the area of vaccine-preventable diseases.
    • Recent publications cover diverse, critical topics such as Lyme disease, pneumococcal vaccination, RSV, and cost-effectiveness of vaccine strategies. This breadth indicates a comprehensive understanding of the field.
  • Impact on Public Health:
    • His work in vaccine-preventable diseases directly contributes to public health improvements, including informing vaccination strategies and addressing vaccine-preventable hospitalizations.
  • Industry and Academic Experience:
    • A balance of pharmaceutical industry experience (Pfizer and GSK) and public health research (UKHSA) highlights his ability to bridge scientific research with practical applications.
    • This unique positioning allows him to contribute to both policy-making and the development of new vaccine technologies.

Education 🎓

Dr. Vyse holds a PhD and MSc, reflecting his robust academic foundation in epidemiology and public health. His educational background has equipped him with the expertise to drive impactful research and clinical applications in his field.

Professional Experience 💼

  • Feb 2017 – Present: Clinical Epidemiologist at Pfizer UK Ltd, supporting the UK Medical Team and global Scientific Affairs for vaccines including pneumococcal, RSV, COVID, meningococcal, and a candidate Lyme vaccine.
  • Jan 2009 – Jan 2017: Global Epidemiologist at GSK Vaccines, contributing to portfolios for meningococcal, DTP, and rotavirus vaccines.
  • May 1993 – Dec 2008: Clinical Scientist at the UK Health Security Agency (formerly Public Health England), focusing on surveillance and epidemiological research for vaccine-preventable infections.

Research Interests On Medicine 🧬

Dr. Vyse’s research interests revolve around vaccine-preventable diseases, with a particular focus on respiratory infections, Lyme borreliosis, and strategies to optimize vaccination coverage in vulnerable populations.

Awards and Recognition 🏆

Dr. Vyse has been recognized for his contributions to epidemiology and vaccine research. His work has garnered significant academic and industry accolades, reflecting his impact on public health initiatives and vaccine development.

Publications 🔖

1. Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus

  • Authors: Vyse, A., Wright, H., Begier, E.
  • Year: 2024
  • Citations: 0

2. Using Catalytic Models to Interpret Age-Stratified Lyme Borreliosis Seroprevalence Data

  • Authors: Vyse, A., Colby, E.
  • Year: 2024
  • Citations: 0

3. Incidence of symptomatic Lyme borreliosis in nine European countries

  • Authors: Angulo, F.J., Colby, E., Lebech, A.-M., Moïsi, J.C., Stark, J.H.
  • Year: 2024
  • Citations: 1

4. Adult risk groups for vaccine-preventable respiratory infections: an overview of the UK environment

  • Authors: Reynard, C., Campling, J., Gordon, A.L., Wright, H., Ellsbury, G.
  • Year: 2024
  • Citations: 0

5. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

  • Authors: Wilson, M., Lucas, A., Mendes, D., Ellsbury, G.F., Perdrizet, J.
  • Year: 2023
  • Citations: 9

6. Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK

  • Authors: Schley, K., Kowalik, J.C., Sullivan, S.M., Tichy, E., Findlow, J.
  • Year: 2023
  • Citations: 0

7. Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?

  • Authors: Neri, M., Brassel, S., Schirrmacher, H., Steuten, L., Hamson, E.
  • Year: 2023
  • Citations: 4

8. A Retrospective Database Study of Lyme Borreliosis Incidence in Poland from 2015 to 2019

  • Authors: Paradowska-Stankiewicz, I., Zbrzezniak, J., Skufca, J., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 5

9. Incidence of Lyme Borreliosis in Germany

  • Authors: Skufca, J., Tran, T.M.P., Brestrich, G., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 2

10. Incidence of Lyme Borreliosis in the Dutch General Practice Population

  • Authors: Houben, E., De Jong, H., Penning-Van Beest, F., Herings, R., Stark, J.H.
  • Year: 2023
  • Citations: 3

Conclusion 🌐

Dr. Andrew Vyse’s work bridges the pharmaceutical industry and public health research, driving innovations in vaccine development and disease prevention. His dedication to epidemiology continues to advance global health outcomes, underpinned by his extensive research, impactful publications, and commitment to public health initiatives.